Abstracts tagged "informatics"

Abstract Number: 0822 • ACR Convergence 2023
From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes
Monica Hannani¹, Zofia Lisowska-Petersen², Morten Karsdal², Cecilie Bager², Anne-Christine Bay-Jensen² and Christian Thudium², ¹University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) is a diverse and multifaceted condition. Despite its widespread incidence, the core mechanisms of the disease remain elusive, and therapeutic interventions are…
Abstract Number: 0852 • ACR Convergence 2023
Screening for Specific Antinuclear Antibodies Using an Artificial Intelligence-enabled Antinuclear Antibody HEp-2 Substrate by Indirect Immunofluorescence Assay
Patrick Vanderboom, Surendra Dasari, Anne Tebo, Melissa Snyder and Ali Duarte-Garcia, Mayo Clinic, Rochester, MN
Background/Purpose: Antinuclear antibodies (ANA) are key biomarkers in the diagnostic evaluation of systemic autoimmune diseases and are widely used in clinical practice. The most accepted…
Abstract Number: 0919 • ACR Convergence 2023
Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Zoha Faheem¹, Giselle Boukhaled², Kieran Manion¹, Carolina Munoz-Grajales³, Carol Nassar¹, Michael Kim¹, Dafna Gladman⁴, Murray Urowitz⁵, Zahi Touma⁶, David Brooks² and Joan Wither⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…
Abstract Number: 1095 • ACR Convergence 2023
Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures
Emma Kersey¹, Jing Li¹, Julia Kay¹, Julia Adler-Milstein¹, Jinoos Yazdany² and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: The American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) EHR-based registry facilitates quality measure calculation and reporting for rheumatology practices in national…
Abstract Number: 1598 • ACR Convergence 2023
Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis
Chen-Yu Lee¹, Caleb Marlin², Xiaoping Yang¹, Tayte Stephens², Alessandra Ida Celia³, Jeff Hodgin⁴, Peter Izmirly⁵, H Michael Belmont⁶, Jill Buyon⁷, Chaim Putterman⁸, Judith James², the Accelerating Medicines Partnership in RA/SLE⁹, Michelle Petri¹⁰, Joel Guthridge², Avi Rosenberg¹¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³John Hopkins University of Medicine, Rome, Italy, ⁴University of Michigan, Ann Arbor, MI, ⁵New York University School of Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Albert Einstein College of Medicine, Bronx, NY, ⁹Multiple, Multiple, ¹⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) leads to end-stage kidney disease (ESKD) in more than 20% of patients despite optimal treatment. Up to 30% of LN patients…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
Abstract Number: 1903 • ACR Convergence 2023
Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry
Katelyn Banschbach¹, Jade Singleton², Esi Morgan² and Xing Wang³, ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital, Seattle, WA, ³Biostatistics Epidemiology and Analytics in Research (BEAR), Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Research databases are missing 25-50% of race and ethnicity, typically related to Black and Hispanic data.1,2The absence of this data can lead to inaccurate…
Abstract Number: 1911 • ACR Convergence 2023
Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study
Catherine Nasrallah¹, Cherish Wilson², Alicia Hamblin¹, Lindsay Jacobsohn¹, Cammie Young³, Cammie Young³, Mary Nakamura⁴, Andrew Gross¹, Judith Ashouri¹, Mehrdad Matloubian¹, Jinoos Yazdany¹ and Gabriela Schmajuk², ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco, Oakland, CA, ⁴UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Improving shared decision-making using a treat-to-target approach, including the use of patient reported outcomes (PROs), is important to providing high quality care for rheumatoid…
Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium
Using the Electronic Health Record to Identify Subjects with Rheumatic Disease
Alysha Taxter¹, Matthew Basiaga², Rajdeep Pooni³, Caitlan Pinotti⁴, Lisa Buckley⁵ and CARRA Registry Investigators⁶, ¹Nationwide Children's Hospital, Columbus, OH, ²Mayo Clinic, Rochester, MN, ³Stanford University, Palo Alto, CA, ⁴Duke, Durham, NC, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶CARRA, Washington, DC
Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium
Validation of Serious Adverse Event Reporting in a Multicenter Registry
Matthew Basiaga¹, Rajdeep Pooni², Caitlan Pinotti³, Lisa Buckley⁴, Alysha Taxter⁵ and CARRA Registry Investigators⁶, ¹Mayo Clinic, Rochester, MN, ²Stanford University, Palo Alto, CA, ³Duke, Durham, NC, ⁴Vanderbilt University Medical Center, Nashville, TN, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶CARRA, Washington, DC
Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…
Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Alysha Taxter¹, Marc Natter², Min-Lee Chang², Laura Schanberg³, Valarie Morrow⁴, Eveline Wu⁵, Tedryl Bumpass⁴, Alex Fist⁴, Meg Waite⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁷ and CARRA Registry Investigators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Boston Children's Hospital, Boston, MA, ⁷CARRA, Washington, DC
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
Abstract Number: 006 • 2023 Pediatric Rheumatology Symposium
Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic
Lauren Harper¹, Alana Goldstein-Leever¹, James Gallup¹, Vidya Sivaraman², Stacy Ardoin¹, Kyla Driest¹, Evan Mulvhihill³ and Alysha Taxter⁴, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³Nemours Children's Hospital, ⁴Nationwide Children's Hospital, Columbus, OH

Background/Purpose: Patients with chronic rheumatic conditions, particularly lupus, have higher rates of depression, which significantly impacts their lives and can lead to poor medication compliance…
Abstract Number: 0242 • ACR Convergence 2022
Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging
Lukas Folle¹, Sara Bayat², Arnd Kleyer³, Filippo Fagni², Lorenz Kapsner⁴, Maja Schlereth⁵, Timo Meinderink², Katharina Breininger⁵, Koray Tascilar³, Gerhard Kroenke³, Michael Uder⁶, MIchael Sticherling⁷, Sebastian Bickelhaupt⁴, Georg Schett⁸, Andreas Maier⁹, Frank Roemer¹⁰ and David Simon³, ¹Friedrich-Alexander-Universitaet Erlangen Nürnberg, Erlangen, Germany, ²University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴University Hospital Erlangen; Institute of Radiology, Erlangen, Germany, ⁵Friedrich-Alexander Universität Erlangen-Nürnberg, Artificial Intelligence in Medical Imaging, Erlangen, Germany, ⁶University Hospital Erlangen; Lehrstuhl für Diagnostische Radiologie, Erlangen, Germany, ⁷University Hospital Erlangen; Institute of Dermatology, Erlangen, Germany, ⁸Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Lehrstuhl für Mustererkennung, Erlangen, Germany, ¹⁰Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany
Background/Purpose: To evaluate (i) whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using MRI data based on…
Abstract Number: 0664 • ACR Convergence 2022
Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients
Prathyusha Bachali¹, Erika Hubbard², Kathryn Kingsmore Allison², Yisha He², Amrie Grammer³ and Peter Lipsky², ¹AMPEL BioSolutions, Redmond, WA, ²AMPEL BioSolutions, Charlottesville, VA, ³AMPEL LLC, Charlottesville, VA
Background/Purpose: Patients with SLE can exhibit considerable clinical heterogeneity. A robust patient stratification approach can help to characterize individual lupus patients more effectively based on…
Abstract Number: 0905 • ACR Convergence 2022
Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry
Eren-Ajani Tshimanga¹, Milena Gianfrancesco², Stefanos Giampanis³, Jing Li², Emma Kersey⁴, Jinoos Yazdany⁵, Beau Norgeot⁶, Gabriela Schmajuk⁷ and Zara Izadi⁴, ¹University of California, Berkeley, Berkeley, CA, ²University of California, San Francisco, San Francisco, CA, ³Anthem, San Francisco, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF, San Francisco, CA, ⁶Anthem, Oakland, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Predicting the trajectory of disease in individuals with RA is difficult, with numerous factors influencing whether a patient may experience higher or lower disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].